Jointly Advancing a New Chapter of the Health Silk Road │ H.E. the Ambassador of Uzbekistan to China Leads a Delegation on an Official Visit and Exchange
On the afternoon of March 13, 2026, at the invitation of two key drivers of China–Uzbekistan cross-border cooperation—Zhongke Zhuli Technology Group and SCO Industrial Development Group,H.E. Farhod Arziev (F. Arziev), Ambassador of the Republic of Uzbekistan to China, led a delegation on an official visit to Guangzhou Concord Cancer Center (GCCC) (hereinafter referred to as “GCCC”). The visit aimed to gain an in-depth understanding of GCCC’s advanced facilities, service system, and operational management in the field of oncology prevention and treatment, while jointly exploring future strategic collaboration opportunities in high-end medical technologies, professional talent development, and modern hospital management. The visit laid a solid foundation for future cooperation between the two sides in the healthcare sector.
The delegation included senior officials from the Embassy of Uzbekistan in China, the Consulate General in Guangzhou, as well as the Director of the Syrdarya Free Economic Zone Administration. Mr. Li Jingze, President of Zhongke Zhuli Technology Group, and Mr. Xiao Di, Executive Vice President, participated throughout the exchange. The delegation was warmly received by Mr. Yang Jianyu, Chairman of Concord Healthcare Group; Mr. Zhang Chengyu, Vice President of the Group and General Manager of GCCC; Professor Qian Chaonan, President of the hospital; and Mr. Li Junwen, Vice President, who engaged in in-depth discussions with the visiting delegation.
Hospital leadership accompanied H.E. the Ambassador of Uzbekistan to China and his delegation on a tour of the hospital.
The delegation conducted a comprehensive tour of GCCC, visiting key areas including the inpatient ward, VIP suites, chemotherapy center, radiotherapy center, and proton therapy center. The visit focused in particular on South China’s first Varian ProBeam Proton Therapy System, which enables the precise delivery of advanced techniques such as intensity-modulated proton therapy (IMPT), achieving “sub-millimeter, stereotactic targeting” of tumor lesions while maximally sparing surrounding healthy tissues.
During the visit, the Ambassador and his delegation gained an in-depth understanding of the proton therapy system.
Leveraging its in-depth collaboration with The University of Texas MD Anderson Cancer Center, GCCC has established a comprehensive clinical system for proton radiotherapy, along with end-to-end quality management protocols aligned with international gold standards. H.E. the Ambassador and accompanying officials expressed strong interest in the hospital’s modern infrastructure, exceptional clean environment management, and patient-centered design philosophy, and spoke highly of the successful introduction and advanced clinical application of cutting-edge technologies such as proton therapy.
After the tour, both sides moved to the conference room for a formal discussion. Mr. Zhang Chengyu, General Manager of Guangzhou Concord Cancer Center (GCCC), warmly welcomed H.E. Ambassador Farhod Arziev and his delegation on behalf of all hospital staff, and introduced GCCC’s initiatives in promoting international medical tourism.
Subsequently, Mr. Yang Jianyu, Chairman of Concord Medical Group, highlighted the Group’s overall strategy and collaborative strengths. The Group has established in-depth partnerships with world-leading medical institutions, including MD Anderson Cancer Center and Mayo Clinic. Serving as a key platform for connecting global cutting-edge oncology technologies, Meizhong Jianhe has accumulated extensive practical experience both domestically and internationally through technical cooperation and capacity building. He emphasized that the hospital actively supports the “Health Silk Road” initiative, and, leveraging its expertise in advanced radiotherapy such as proton therapy and long-term collaboration with top international cancer centers, looks forward to establishing a long-term, stable partnership with the healthcare sector in Uzbekistan. Both sides aim to deepen exchanges and mutual learning in areas such as collaborative innovation in cancer prevention and treatment technologies, joint training of high-level medical professionals, co-development of key disciplines, and sharing of hospital management experience, working together to improve health outcomes for people in both countries and the broader region.
Mr. Yang Jianyu, Chairman of Concord Medical Group, Delivered a Speech at the Meeting.
H.E. Ambassador Farhod Arziev then delivered a speech, praising GCCC’s professionalism, technological depth, and internationally advanced facilities and management standards. He noted that Uzbekistan is a steadfast supporter and key partner of the “Belt and Road” Initiative, and that practical cooperation between China and Uzbekistan in healthcare continues to deepen.
The Ambassador expressed that this visit was an invaluable opportunity for exchange and learning. Uzbekistan is eager to draw on China’s successful experience in cancer prevention and treatment, particularly in advanced radiotherapy technologies and modern hospital management. He looks forward to using this visit as a platform to explore concrete cooperation projects, including planning and construction of oncology centers, bilateral medical talent training, and building telemedicine collaboration platforms, jointly promoting high-quality development of cancer prevention and treatment in Central Asia. He further suggested that follow-up engagements with the Ministry of Health of Uzbekistan and relevant medical institutions could explore multi-level cooperation models, including joint construction and technical operation support, to advance high-quality oncology care in the region.
Left: H.E. Mr. Farhod Arziev, Ambassador of the Republic of Uzbekistan to ChinaRight: Mr. Yang Jianyu, Chairman of Concord Medical Group
The successful visit of H.E. the Ambassador of Uzbekistan to China and his delegation not only highlighted Guangzhou Concord Cancer Center’s (GCCC) outstanding overall capabilities and growing international influence, but also marked a key step in the hospital’s proactive implementation of the national “Belt and Road” Initiative and the expansion of its global healthcare collaboration network. Looking ahead, GCCC will continue to uphold its principles of openness, collaboration, and innovation, working hand-in-hand with medical institutions in Belt and Road countries, including Uzbekistan, to explore deeper and broader cooperation models, and to continuously contribute its professional expertise to building a global community of health for all.
